Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2025)

Candel Therapeutics has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 16066000.0 for Q4 2025.

• Income from Continuing Operations for Q4 2025 came in at 16066000.0, down 94.95% year-over-year; the trailing twelve-month figure through Dec 2025 was 46470000.0 (down 35.19% YoY), and the FY2025 annual result was 46470000.0, down 35.19% from the prior year.
• Income from Continuing Operations came in at 16066000.0 for Q4 2025 at Candel Therapeutics, down from 12415000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 4669000.0 in Q1 2021 to a low of 16066000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 9018000.0 (2023), against an average of 9037000.0.
• Across the five-year window, Income from Continuing Operations slumped 197.01% in 2021 and increased 22.08% in 2024, its largest moves.
• Candel Therapeutics' Income from Continuing Operations stood at 7751000.0 in 2021, then retreated by 1.6% to 7875000.0 in 2022, then tumbled by 34.3% to 10576000.0 in 2023, then climbed by 22.08% to 8241000.0 in 2024, then tumbled by 94.95% to 16066000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 16066000.0 (Q4 2025), 12415000.0 (Q3 2025), and 10487000.0 (Q2 2025), per Business Quant data.